Merck and Isomorphic Labs to search for cancer molecules via IsoDDE
Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .
SI molecule design is becoming a separate link in the pharma pipeline: Merck is outsourcing it to Isomorphic while keeping preclinical, clinical and commercialization work.
Merck (MSD) and Isomorphic Labs announced a research collaboration. Isomorphic will make in silico predictions and supply molecular designs through its IsoDDE engine using Merck's proprietary datasets. Merck will handle preclinical and clinical development, manufacturing and commercialization. The goal is small molecules against a cancer target of "strategic importance". Terms include an upfront payment, payments for research, development, regulatory and commercial milestones, and tiered royalties. Isomorphic has an option to co-fund development in exchange for higher royalties. The deal was announced days after Isomorphic raised $5 billion and adds Merck to a partner list that includes Eli Lilly, J&J and Novartis.
Sources 1